NSABP-B-47 Hormonal/Endocrine Therapy Form (Form HT) A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer Source Form: NCI FormBuilder:


Versions (2) ▾
  1. 12/18/14
  2. 1/9/15
Uploaded on:

January 9, 2015

No DOI assigned. To request one please log in.
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT01275677 Treatment - NSABP-B-47 Hormonal/Endocrine Therapy Form (Form HT) - 3161813v1.0

This paper worksheet may be completed to facilitate the entry of the information in NSABP Coordinator Online. Partially completed worksheets may be saved in Coordinator Online. DO NOT SUBMIT THIS WORKSHEET VIA FAX OR MAIL. This form applies ONLY to women with ER-positive and/or PgR-positive tumors. This form should be submitted through 6 years on study, even if all postoperative adjuvant hormonal treatment is reported to have ended. Do not report hormonal therapy that was taken to treat breast cancer recurrence or second primary cancer

Unnamed Module 1
Reporting Period
Since being entered on study, has the patient received any postoperative adjuvant hormonal treatment? (If no, omit all remaining questions)
Was endocrine therapy use assessed at the specified time point (If yes, complete the following table)
Was agent administered

Similar models